BGLC Company Profile and Key Details

Q: Who are the executives of BGLC?

Mr. Sook Keng YeohChief Executive Officer & DirectorMs. Yee Meng WongPres & DirectorMs. Wei Li LeongChief Financial Officer & Principal Accounting OfficerDr. Choong-Chin LiewCo-Founder, Chief Scientist & Scientific AdviserDr. Yee Meng WongPres & DirectorMr. Liong Tai TanChief Operating Officer & Executive DirectorMr. Kwan Wah ChanMarketing Mang.Mr. Too Kam ThamManaging Director

NASDAQ : BGLC

BioNexus Gene Lab

$2.28

0.0798+3.63%

At Close 4:00 PM

67.46

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

BioNexus Gene Lab Corp. (BGLC) stock surged +3.63%, trading at $2.28 on NASDAQ, up from the previous close of $2.20. The stock opened at $2.15, fluctuating between $2.15 and $2.28 in the recent session.

Stock Snapshot

2.2001

Prev. Close

4.23M

Market Cap

2.1512

Day Low

-1.42

P/E Ratio

-1.61

EPS (TTM)

-0.08

Cash Flow per Share

2.15

Open

1.86M

Number of Shares

2.28

Day High

63.05%

Free Float in %

0.55

Book Value

3.59K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 20, 2026	2.26	2.28	2.15	2.28	3.64K
Apr 17, 2026	2.20	2.20	2.20	2.20	1.4K
Apr 16, 2026	2.19	2.24	2.18	2.18	8.36K
Apr 14, 2026	2.17	2.17	2.17	2.17	1.26K
Apr 13, 2026	2.17	2.26	2.17	2.26	2.71K
Apr 10, 2026	2.30	2.30	2.15	2.18	3.5K
Apr 09, 2026	2.16	2.26	2.15	2.25	3.4K
Apr 08, 2026	2.30	2.31	2.30	2.30	2.55K
Apr 07, 2026	2.30	2.30	2.30	2.30	940
Apr 06, 2026	2.21	2.26	2.21	2.26	1.17K
Apr 02, 2026	2.27	2.27	2.19	2.21	1.59K
Apr 01, 2026	2.35	2.35	2.27	2.27	2.59K
Mar 31, 2026	2.15	2.20	2.14	2.14	5.48K
Mar 30, 2026	2.33	2.33	2.32	2.32	2.07K
Mar 27, 2026	2.46	2.46	2.35	2.35	2.55K
Mar 25, 2026	2.46	2.55	2.46	2.49	2.32K
Mar 24, 2026	2.59	2.60	2.53	2.59	904
Mar 23, 2026	2.62	2.68	2.56	2.65	4.29K
Mar 20, 2026	2.48	2.57	2.44	2.44	593
Mar 19, 2026	2.50	2.62	2.50	2.56	3.09K

Contact Details

Kuala Lumpur, 59200

Malaysia

https://www.bionexusgenelab.com 601 221 26512

About Company

BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments. The company, through its subsidiary, BioNexus Gene Lab Sdn. Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

Stock Peers

IDXX

-6.19-1.05%

IDEXX Laboratories, Inc.$583.06 MEDP

7.84+1.51%

Medpace Holdings, Inc.$528.44 NTRA

-0.66-0.32%

Natera, Inc.$207.74 ILMN

-1.64-1.22%

Illumina, Inc.$132.86 ICLR

-2.56-2.14%

ICON Public Limited Company$117.12 EXAS

Exact Sciences Corporation$104.91 GH

0.71+0.79%

Guardant Health, Inc.$91.07 BLLN

7.54+9.49%

BillionToOne, Inc.$86.97 TWST

2.07+3.46%

Twist Bioscience Corporation$61.88 RDNT

-2.54-4.21%

RadNet, Inc.$57.85

Company Overview

BioNexus Gene Lab Corp. (NASDAQ:BGLC) closed at $2.28 USD, gaining $0.08 (3.63%) from the previous close of $2.20. The stock is currently mid-range between its 52-week high and low $1.92 and $15.60. With a market capitalization of about $4.23 million, BioNexus Gene Lab Corp. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.64). Key stats such as the average daily volume over the past year has been around 19.94 thousand shares, volume is running light vs its 52-week average. Headquartered in Kuala Lumpur, None, BioNexus Gene Lab Corp. operates in the Healthcare sector and the Medical - Diagnostics & Research industry. Led by CEO Set Fui Chong, the company employs approximately 30 people and listed since January 08, 2021. BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn.

Dividend & Fair Value

BioNexus Gene Lab Corp. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$8.03. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

BioNexus Gene Lab Corp. generated EPS of -$1.28 over the past year. Five-year average earnings growth is -21.27%.

Frequently Asked Questions

What is the current BioNexus Gene Lab Corp. (BGLC) stock price?

BioNexus Gene Lab Corp. (NASDAQ: BGLC) stock price is $2.28 in the last trading session. During the trading session, BGLC stock reached the peak price of $2.28 while $2.15 was the lowest point it dropped to. The percentage change in BGLC stock occurred in the recent session was 3.63% while the dollar amount for the price change in BGLC stock was $0.08.

BGLC's industry and sector of operation?

The NASDAQ listed BGLC is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector. BioNexus Gene Lab Corp. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of BGLC?

Mr. Sook Keng Yeoh
Chief Executive Officer & Director
Ms. Yee Meng Wong
Pres & Director
Ms. Wei Li Leong
Chief Financial Officer & Principal Accounting Officer
Dr. Choong-Chin Liew
Co-Founder, Chief Scientist & Scientific Adviser
Dr. Yee Meng Wong
Pres & Director
Mr. Liong Tai Tan
Chief Operating Officer & Executive Director
Mr. Kwan Wah Chan
Marketing Mang.
Mr. Too Kam Tham
Managing Director

How BGLC did perform over past 52-week?

BGLC's closing price is 18.75% higher than its 52-week low of $1.92 where as its distance from 52-week high of $15.60 is -85.39%.

How many employees does BGLC have?

Number of BGLC employees currently stands at 30.

Link for BGLC official website?

Official Website of BGLC is: https://www.bionexusgenelab.com

How do I contact BGLC?

BGLC could be contacted at phone 601 221 26512 and can also be accessed through its website. BGLC operates from Tower B, Vertical Business Suite, Kuala Lumpur, 59200, Malaysia.

How many shares of BGLC are traded daily?

BGLC stock volume for the day was 3.59K shares. The average number of BGLC shares traded daily for last 3 months was 19.94K.

What is the market cap of BGLC currently?

The market value of BGLC currently stands at $4.23M with its latest stock price at $2.28 and 1.86M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Price Chart

Stock Price Today

Stock Snapshot

2.2001

Prev. Close

4.23M

Market Cap

2.1512

Day Low

-1.42

P/E Ratio

-1.61

EPS (TTM)

-0.08

Cash Flow per Share

2.15

Open

1.86M

Number of Shares

2.28

Day High

63.05%

Free Float in %

0.55

Book Value

3.59K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 20, 2026	2.26	2.28	2.15	2.28	3.64K
Apr 17, 2026	2.20	2.20	2.20	2.20	1.4K
Apr 16, 2026	2.19	2.24	2.18	2.18	8.36K
Apr 14, 2026	2.17	2.17	2.17	2.17	1.26K
Apr 13, 2026	2.17	2.26	2.17	2.26	2.71K
Apr 10, 2026	2.30	2.30	2.15	2.18	3.5K
Apr 09, 2026	2.16	2.26	2.15	2.25	3.4K
Apr 08, 2026	2.30	2.31	2.30	2.30	2.55K
Apr 07, 2026	2.30	2.30	2.30	2.30	940
Apr 06, 2026	2.21	2.26	2.21	2.26	1.17K
Apr 02, 2026	2.27	2.27	2.19	2.21	1.59K
Apr 01, 2026	2.35	2.35	2.27	2.27	2.59K
Mar 31, 2026	2.15	2.20	2.14	2.14	5.48K
Mar 30, 2026	2.33	2.33	2.32	2.32	2.07K
Mar 27, 2026	2.46	2.46	2.35	2.35	2.55K
Mar 25, 2026	2.46	2.55	2.46	2.49	2.32K
Mar 24, 2026	2.59	2.60	2.53	2.59	904
Mar 23, 2026	2.62	2.68	2.56	2.65	4.29K
Mar 20, 2026	2.48	2.57	2.44	2.44	593
Mar 19, 2026	2.50	2.62	2.50	2.56	3.09K

Contact Details

Kuala Lumpur, 59200

Malaysia

https://www.bionexusgenelab.com 601 221 26512

About Company

Stock Peers

IDXX

-6.19-1.05%

IDEXX Laboratories, Inc.$583.06 MEDP

7.84+1.51%

Medpace Holdings, Inc.$528.44 NTRA

-0.66-0.32%

Natera, Inc.$207.74 ILMN

-1.64-1.22%

Illumina, Inc.$132.86 ICLR

-2.56-2.14%

ICON Public Limited Company$117.12 EXAS

Exact Sciences Corporation$104.91 GH

0.71+0.79%

Guardant Health, Inc.$91.07 BLLN

7.54+9.49%

BillionToOne, Inc.$86.97 TWST

2.07+3.46%

Twist Bioscience Corporation$61.88 RDNT

-2.54-4.21%

RadNet, Inc.$57.85

Company Overview

Technical Performance

BGLC has shown weak momentum, losing -11.73% over the past week and -35.48% over the past quarter, though year-to-date performance is down -16.2%. Short-term trend indicators are bullishly aligned (SMA20 7.55%, SMA50 -21.53%, SMA200 -42.82%). The stock’s 14-day RSI is 45.11 (neutral), while the ATR of 0.18 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -83.97% below its high and over 30.21% above its low. Average 10-day trading volume of 3.47 thousand shares is below the 3-month average of 15.27 thousand, indicating normal recent market interest.

Valuation Metrics

BioNexus Gene Lab Corp. trades at a P/E ratio of -1.42, slightly below the S&P 500 average, with a price-to-sales ratio of 0.57 and a price-to-book ratio of 0.49 suggesting the stock is closer to book value. The P/FCF stands at -2.23, also below market averages.

Dividend & Fair Value

Earnings & Analyst Outlook

BioNexus Gene Lab Corp. generated EPS of -$1.28 over the past year. Five-year average earnings growth is -21.27%.

Shareholding & Insider Activity

BioNexus Gene Lab Corp. has 1.80 million shares outstanding. The public float is 1.13 million shares, elevated short interest at 2.33% of float. This equals 41.74 thousand shares. The short ratio is 0.24 days. Institutional investors hold 1.09% of the float. Insiders own 51.11%.

Financial & Profitability Overview

Over the trailing twelve months, BioNexus Gene Lab generated $9.77M in revenue, or $0.62 per share. Gross margin was 13.61%, operating margin -26.54%, and net profit margin -26.91%. Returns are negative, with ROA at 0.00% and ROE at -27.22%.
On valuation metrics, BioNexus Gene Lab trades at a P/E of -1.42, P/S of 0.57 and P/B of 0.49. The current ratio is 10.46 and quick ratio is 9.16. Operationally, the company’s inventory turnover is 9.37 and cash conversion cycle is 70.73 days. Debt-to-equity is 0.02, supported by a cash flow-to-debt ratio of -10.42.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, BioNexus Gene Lab posted revenue of $9.77M, down slightly from $10.93M in the prior quarter. Gross profit was $1.33M (margin 13.61%). Operating income was - $2.59M (margin -26.5%). Net income was- $2.63M (EPS - $0.17).
Total assets were $0.00, with equity of $9.66M. Financials further reflected weakness, with operating cash flow of - $1.30M, free cash flow of - $1.30M, and capital expenditures of $0.00.

Price Forecast & Outlook

Our AI price prediction model suggests that BioNexus Gene Lab Corp. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -5.7%, with price expected at $2.15 by May 04, 2026, within a range of $1.99 to $2.31 3-Month Outlook: Projected rise of 33.77%, reaching $3.05 by July 17, 2026, with a range of $2.58 to $3.37. 1-Year Outlook: Projected gain of 10.53%, with price at $2.52 by April 20, 2027, within a range of $0.00 to $5.20.

Key Takeaways

BioNexus Gene Lab Corp. (NASDAQ:BGLC) shares are down -16.2% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows BioNexus Gene Lab Corp. trading at a premium to the broader market with a P/E of -1.42. Our AI forecast model points to short-term weakness (-5.7% over two weeks), a medium-term rise (33.77% over three months), and a longer-term gain (10.53% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current BioNexus Gene Lab Corp. (BGLC) stock price?

BGLC's industry and sector of operation?

Who are the executives of BGLC?

How BGLC did perform over past 52-week?

BGLC's closing price is 18.75% higher than its 52-week low of $1.92 where as its distance from 52-week high of $15.60 is -85.39%.

How many employees does BGLC have?

Number of BGLC employees currently stands at 30.

Link for BGLC official website?

Official Website of BGLC is: https://www.bionexusgenelab.com

How do I contact BGLC?

BGLC could be contacted at phone 601 221 26512 and can also be accessed through its website. BGLC operates from Tower B, Vertical Business Suite, Kuala Lumpur, 59200, Malaysia.

How many shares of BGLC are traded daily?

BGLC stock volume for the day was 3.59K shares. The average number of BGLC shares traded daily for last 3 months was 19.94K.

What is the market cap of BGLC currently?

The market value of BGLC currently stands at $4.23M with its latest stock price at $2.28 and 1.86M of its shares outstanding.

Employees	30
Beta	2.31
Sales or Revenue	$9.77M
5Y Sales Change%	159.238%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Medical - Diagnostics & Research

Employees	30
Beta	2.31
Sales or Revenue	$9.77M
5Y Sales Change%	159.238%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Medical - Diagnostics & Research

BGLC Company Profile and Key Details

BioNexus Gene Lab

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Dividend & Fair Value

Earnings & Analyst Outlook

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Valuation Metrics

Technical Performance

Shareholding & Insider Activity

Key Takeaways

Price Forecast & Outlook

Financial & Profitability Overview

Quarterly Financial Highlights